111 related articles for article (PubMed ID: 29044829)
1. Enzyme replacement therapy prevents loss of bone and fat mass in murine homocystinuria.
Majtan T; Park I; Bublil EM; Kraus JP
Hum Mutat; 2018 Feb; 39(2):210-218. PubMed ID: 29044829
[TBL] [Abstract][Full Text] [Related]
2. Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy.
Majtan T; Park I; Cox A; Branchford BR; di Paola J; Bublil EM; Kraus JP
FASEB J; 2019 Nov; 33(11):12477-12486. PubMed ID: 31450979
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.
Majtan T; Hůlková H; Park I; Krijt J; Kožich V; Bublil EM; Kraus JP
FASEB J; 2017 Dec; 31(12):5495-5506. PubMed ID: 28821635
[TBL] [Abstract][Full Text] [Related]
4. Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria.
Majtan T; Jones W; Krijt J; Park I; Kruger WD; Kožich V; Bassnett S; Bublil EM; Kraus JP
Mol Ther; 2018 Mar; 26(3):834-844. PubMed ID: 29398487
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of PEGylated truncated human cystathionine beta-synthase for treatment of homocystinuria.
Majtan T; Bublil EM; Park I; Arning E; Bottiglieri T; Glavin F; Kraus JP
Life Sci; 2018 May; 200():15-25. PubMed ID: 29526799
[TBL] [Abstract][Full Text] [Related]
6. Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model.
Wang L; Chen X; Tang B; Hua X; Klein-Szanto A; Kruger WD
Hum Mol Genet; 2005 Aug; 14(15):2201-8. PubMed ID: 15972722
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement with PEGylated cystathionine β-synthase ameliorates homocystinuria in murine model.
Bublil EM; Majtan T; Park I; Carrillo RS; Hůlková H; Krijt J; Kožich V; Kraus JP
J Clin Invest; 2016 Jun; 126(6):2372-84. PubMed ID: 27183385
[TBL] [Abstract][Full Text] [Related]
8. Betaine supplementation is less effective than methionine restriction in correcting phenotypes of CBS deficient mice.
Gupta S; Wang L; Kruger WD
J Inherit Metab Dis; 2016 Jan; 39(1):39-46. PubMed ID: 26231230
[TBL] [Abstract][Full Text] [Related]
9. Long-term uninterrupted enzyme replacement therapy prevents liver disease in murine model of severe homocystinuria.
Park I; Hůlková H; Krijt J; Kožich V; Bublil EM; Majtan T
Hum Mutat; 2020 Sep; 41(9):1662-1670. PubMed ID: 32623804
[TBL] [Abstract][Full Text] [Related]
10. Long-term betaine therapy in a murine model of cystathionine beta-synthase deficient homocystinuria: decreased efficacy over time reveals a significant threshold effect between elevated homocysteine and thrombotic risk.
Maclean KN; Jiang H; Greiner LS; Allen RH; Stabler SP
Mol Genet Metab; 2012 Mar; 105(3):395-403. PubMed ID: 22192524
[TBL] [Abstract][Full Text] [Related]
11. Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function.
Majtan T; Olsen T; Sokolova J; Krijt J; Křížková M; Ida T; Ditrói T; Hansikova H; Vit O; Petrak J; Kuchař L; Kruger WD; Nagy P; Akaike T; Kožich V
Redox Biol; 2024 Jul; 73():103222. PubMed ID: 38843767
[TBL] [Abstract][Full Text] [Related]
12. Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies.
Bublil EM; Majtan T
Biochimie; 2020 Jun; 173():48-56. PubMed ID: 31857119
[TBL] [Abstract][Full Text] [Related]
13. The effect of dietary modulation of sulfur amino acids on cystathionine β synthase-deficient mice.
Kruger WD; Gupta S
Ann N Y Acad Sci; 2016 Jan; 1363(1):80-90. PubMed ID: 26599618
[TBL] [Abstract][Full Text] [Related]
14. An orally administered enzyme therapeutic for homocystinuria that suppresses homocysteine by metabolizing methionine in the gastrointestinal tract.
Skvorak K; Mitchell V; Teadt L; Franklin KA; Lee HO; Kruse N; Huitt-Roehl C; Hang J; Du F; Galanie S; Guan S; Aijaz H; Zhang N; Rajkovic G; Kruger WD; Ismaili MHA; Huisman G; McCluskie K; Silverman AP
Mol Genet Metab; 2023 Aug; 139(4):107653. PubMed ID: 37463544
[TBL] [Abstract][Full Text] [Related]
15. Genetic and Pharmacological Modulation of Cellular Proteostasis Leads to Partial Functional Rescue of Homocystinuria-Causing Cystathionine-Beta Synthase Variants.
Collard R; Majtan T
Mol Cell Biol; 2023; 43(12):664-674. PubMed ID: 38051092
[TBL] [Abstract][Full Text] [Related]
16. Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.
Gupta S; Wang L; Anderl J; Slifker MJ; Kirk C; Kruger WD
Hum Mutat; 2013 Aug; 34(8):1085-93. PubMed ID: 23592311
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: possible implications for cardiovascular outcomes.
Jiang H; Stabler SP; Allen RH; Maclean KN
Mol Genet Metab; 2012 Sep; 107(1-2):55-65. PubMed ID: 22633282
[TBL] [Abstract][Full Text] [Related]
18. Interplay of Enzyme Therapy and Dietary Management of Murine Homocystinuria.
Park I; Bublil EM; Glavin F; Majtan T
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32971905
[TBL] [Abstract][Full Text] [Related]
19. Long-term functional correction of cystathionine β-synthase deficiency in mice by adeno-associated viral gene therapy.
Lee HO; Salami CO; Sondhi D; Kaminsky SM; Crystal RG; Kruger WD
J Inherit Metab Dis; 2021 Nov; 44(6):1382-1392. PubMed ID: 34528713
[TBL] [Abstract][Full Text] [Related]
20. Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria.
Majtan T; Kožich V; Kruger WD
Br J Pharmacol; 2023 Feb; 180(3):264-278. PubMed ID: 36417581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
